Literature DB >> 26160528

Intra-silicone oil injection of methotrexate at the end of vitrectomy for advanced proliferative diabetic retinopathy.

K Ghasemi Falavarjani1, M Modarres1, A Hadavandkhani1, A Karimi Moghaddam1.   

Abstract

PURPOSE: To evaluate the role of methotrexate (MTX) injected into the silicone oil at the end of pars plana vitrectomy for advanced proliferative diabetic retinopathy (PDR).
METHODS: In this prospective comparative interventional study, eyes with severe diabetic tractional macular detachment or combined tractional/rhegmatogenous retinal detachment were included. Standard 20 gauge pars plana vitrectomy, and retinal reattachment was performed. In the case group, 250 μg MTX was injected into the silicone oil at the end of surgery. The rate of retinal re-detachment associated with fibrovascular proliferation or proliferative vitreoretinopathy (PVR) was assessed.
RESULTS: Overall, 38 eyes of 35 patients (19 cases and 19 controls) were studied. The two groups were matched for age, sex, preoperative visual acuity, and the type of surgery (vitrectomy alone vs combined phacoemulsification/vitrectomy). Retinal re-detachment with fibrovascular proliferation or PVR occurred in seven eyes (36.8%) in the MTX group and eight eyes (42.1%) in the control group (P = 0.74). Mean change in visual acuity was 0.04 ± 0.71 and 0.39 ± 0.70 logMAR in the MTX and the control group, respectively (P = 0.14). The rate of improvement or worsening of visual acuity was similar between the two groups (P = 0.51 and P = 0.12).
CONCLUSION: Intra-silicone injection of MTX at the end of vitrectomy for retinal detachment associated with severe PDR did not reduce the risk of postoperative retinal detachment due to the fibrous or fibrovascular proliferations.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26160528      PMCID: PMC4565943          DOI: 10.1038/eye.2015.114

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  19 in total

1.  Intravitreal triamcinolone acetonide as an additional tool in pars plana vitrectomy for proliferative diabetic retinopathy.

Authors:  J B Jonas; A Söfker; R Degenring
Journal:  Eur J Ophthalmol       Date:  2003-06       Impact factor: 2.597

2.  Intravitreal methotrexate as an adjunctive treatment of intraocular lymphoma.

Authors:  B C Fishburne; D J Wilson; J T Rosenbaum; E A Neuwelt
Journal:  Arch Ophthalmol       Date:  1997-09

3.  Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Clinical application of results of a randomized trial--Diabetic Retinopathy Vitrectomy Study Report 4. The Diabetic Retinopathy Vitrectomy Study Research Group.

Authors: 
Journal:  Ophthalmology       Date:  1988-10       Impact factor: 12.079

4.  Intraocular methotrexate in ocular diseases other than primary central nervous system lymphoma.

Authors:  Paul W Hardwig; Jose S Pulido; Jay C Erie; Keith H Baratz; Helmut Buettner
Journal:  Am J Ophthalmol       Date:  2006-11       Impact factor: 5.258

5.  Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy.

Authors:  J B Jonas; J K Hayler; A Söfker; S Panda-Jonas
Journal:  Am J Ophthalmol       Date:  2001-04       Impact factor: 5.258

6.  Intravitreal chemotherapy for the treatment of recurrent intraocular lymphoma.

Authors:  M D de Smet; V S Vancs; D Kohler; D Solomon; C C Chan
Journal:  Br J Ophthalmol       Date:  1999-04       Impact factor: 4.638

7.  Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients.

Authors:  C M Samson; N Waheed; S Baltatzis; C S Foster
Journal:  Ophthalmology       Date:  2001-06       Impact factor: 12.079

8.  Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement.

Authors:  Justine R Smith; James T Rosenbaum; David J Wilson; Nancy D Doolittle; Tali Siegal; Edward A Neuwelt; Jacob Pe'er
Journal:  Ophthalmology       Date:  2002-09       Impact factor: 12.079

9.  The safety of intraocular methotrexate in silicone-filled eyes.

Authors:  Paul W Hardwig; Jose S Pulido; Sophie J Bakri
Journal:  Retina       Date:  2008-10       Impact factor: 4.256

Review 10.  Molecular action of methotrexate in inflammatory diseases.

Authors:  Edwin S L Chan; Bruce N Cronstein
Journal:  Arthritis Res       Date:  2002-03-19
View more
  4 in total

1.  Intravitreal injection of methotrexate in persistent diabetic macular edema: a 6-month follow-up study.

Authors:  Khalil Ghasemi Falavarjani; Sara Golabi; Mehdi Modarres
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-05-05       Impact factor: 3.117

2.  Intravitreal methotrexate for the treatment of proliferative vitreoretinopathy.

Authors:  Jeffrey David Benner; David Dao; John W Butler; Kelli I Hamill
Journal:  BMJ Open Ophthalmol       Date:  2019-04-01

3.  Long-Term Outcomes and Risk Factors for Severe Vision Loss in Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy (ADNIV).

Authors:  Timothy M Boyce; S Scott Whitmore; Katayoun Varzavand; Stephen R Russell; Elliott H Sohn; James C Folk; Edwin M Stone; Ian C Han
Journal:  Am J Ophthalmol       Date:  2021-07-21       Impact factor: 5.488

4.  Intravitreal methotrexate infusion for proliferative vitreoretinopathy.

Authors:  Ama Sadaka; Robert A Sisk; James M Osher; Okan Toygar; Melinda K Duncan; Christopher D Riemann
Journal:  Clin Ophthalmol       Date:  2016-09-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.